Tenderwize
Wróć do wyszukiwania

Open House Biologics Discount Agreement for Lutropin alfa / Follitropin alfa

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 278 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-09 - Lutropin alfa / Follitropin alfa (Wirkstoffkombination)

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

Portal submission is not allowed; contracts must be submitted by email with qualified electronic signature or by post...

Only pharmaceutical undertakings meeting the AMG and authorisation requirements may participate.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply-related Open House discount agreements for pharmaceutical products.
  • Product scope: Lutropin alfa / Follitropin alfa combination.
Pokaż pełne podsumowanie

This is an Open House supply arrangement by Techniker Krankenkasse (with HEK and hkk listed as participating buyers) for pharmaceutical products, specifically the Lutropin alfa / Follitropin alfa combination. The contract is non-exclusive, with uniform terms and no individual negotiations. The term is up to 24 months from 2025-06-01 and ends no later than 2027-05-31. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post. No contract value is stated.

Ryzyka

Portal submission is not allowed; contracts must be submitted by email with qualified electronic signature or by post...

Only pharmaceutical undertakings meeting the AMG and authorisation requirements may participate.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal products.
  • Applicant must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal products or otherwise be entitled to place them on the market in its own name.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Biologics Discount Agreement for Lutropin alfa / Follitropin alfa

Single lot covering discount agreements under Section 130a(8) SGB V for the Lutropin alfa / Follitropin alfa medicinal product combination. The notice states the arrangement is open to all suitable pharmaceutical companies meeting the stated conditions, with no exclusivity and no individual negotiation. Scope and eligibility details are in the participation and contract documents.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

May 2025 - May 2027

Kategoria

Pharmaceutical products

Termin

Deadline May 30, 2027

Szczegóły zamówienia

Data publikacji
22 Apr 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
262656-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3